text: Immunogen (IMGN) Showing Signs Of A Dead Cat Bounce Today - TheStreet
  Immunogen (IMGN) Showing Signs Of A Dead Cat Bounce Today
  Trade-Ideas LLC identified Immunogen (IMGN) as a "dead cat bounce" (down big yesterday but up big today) candidate
  Trade-Ideas LLC identified Immunogen ( IMGN) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Immunogen as such a stock due to the following factors:
  IMGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.4 million.
  IMGN has traded 194,507 shares today.
  IMGN is up 3.1% today.
  IMGN was down 43.7% yesterday.
  ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Currently there are 5 analysts that rate Immunogen a buy, 2 analysts rate it a sell, and 4 rate it a hold.
  The average volume for Immunogen has been 1.3 million shares per day over the past 30 days. Immunogen has a market cap of $921.7 million and is part of the health care sector and drugs industry. The stock has a beta of 1.84 and a short float of 14.4% with 3.38 days to cover. Shares are down 26.9% year-to-date as of the close of trading on Thursday.
  Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 27.67%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 100.00% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  The revenue fell significantly faster than the industry average of 40.9%. Since the same quarter one year prior, revenues fell by 23.3%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.